Thus, through our study, we have evaluated the immunohistochemical expression of CD133 and NANOG markers at the level of tumor cells in cutaneous melanoma and performed an analysis of the expression of the two markers and the epidemiological, histological, and biological parameters of the cases included in the study. The gene discussed is NANOG; the disease is cutaneous melanoma.